Press Release: FDA approves Novartis Kisqali(R) -2-
Werte in diesem Artikel
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," "to reduce," "remains," "continue," "transform," "evaluate," "likelihood," "ensuring," "updates, " "should," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Kisqali in combination with an aromatase inhibitor (AI), or regarding potential future revenues from such product. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Kisqali in combination with an AI will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Kisqali in combination with an AI will be commercially successful in the future. In particular, our expectations regarding Kisqali in combination with an AI could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.
References
1. Kisqali (ribociclib) Prescribing information. East Hanover, New Jersey,
USA: Novartis Pharmaceuticals Corporation; September 2024.
2. Tarantino P, Rugo HS, Curigliano G, et al. Characteristics of real-world
NATALEE and monarchE eligible populations: A US electronic health records
database analysis. Poster presented at the European Society for Medical
Oncology Congress; September 13-17, 2024; Barcelona, Spain.
3. Slamon D, Stroyakovskiy D, Yardley D, et al. Ribociclib and endocrine
therapy as adjuvant treatment in patients with HR+/HER2- early breast
cancer: primary results from the Phase III NATALEE trial. Presented at
the American Society of Clinical Oncology Annual Meeting; June 2, 2023;
Chicago, USA.
4. Hortobagyi G, Stroyakovskiy D, Yardley DA, et al. Ribociclib (RIB) +
nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients
with HR+/HER2- early breast cancer: final invasive disease-free survival
(iDFS) analysis from the NATALEE trial. Presented at San Antonio Breast
Cancer Symposium (SABCS); December 8, 2023; San Antonio, USA.
5. Slamon D et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med. 2024;390:1080-1091. doi: 10.1056/NEJMoa2305488
6. Yardley D, Untch M, et al. Baseline (BL) characteristics and efficacy
endpoints for patients (pts) with node-negative (N0) HR+/HER2- early
breast cancer (EBC) in NATALEE. Presented at the American Society of
Clinical Oncology Annual Meeting; May 31, 2024; Chicago, USA.
7. Fasching PA. Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase
Inhibitor (NSAI) in Patients (Pts) With HR+/HER2- Early Breast Cancer
(EBC): 4-Year Outcomes From the NATALEE Trial. LBA13. Proffered Paper
presented at the European Society for Medical Oncology Congress;
September 16, 2024; Barcelona, Spain.
8. Pan H et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping
Endocrine Therapy at 5 Years. N Engl J Med. 2017;377 (suppl 19):1836 846.
doi: 10.1056/NEJMoa1701830
9. Wangchinda P, Ithimakin S. Factors that predict recurrence later than 5
years after initial treatment in operable breast cancer. World J Surg
Oncol. 2016;14(1):223. doi: 10.1186/s12957-016-0988-0
10. Yardley DA, Yap YS, et al. Pooled exploratory analysis of survival in
patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral
metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET)
in the MONALEESA (ML) trials. Poster presented at the European Society of
Medical Oncology Congress; September 9-13, 2022; Paris, France.
11. Neven P, Fasching PA, et al. Updated overall survival (OS) results from
the first-line (1L) population in the Phase III MONALEESA-3 trial of
postmenopausal patients with HR+/HER2- advanced breast cancer (ABC)
treated with ribociclib (RIB) + fulvestrant (FUL). Mini oral presented at
the European Society for Medical Oncology Breast Cancer Congress; May 4,
2022; Paris, France.
12. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with
Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med.
2022;386(10):942-950. doi:10.1056/NEJMoa2114663
13. Hortobagyi GN, et al. Overall survival (OS) results from the phase III
MONALEESA (ML)-2 trial of postmenopausal patients with hormone receptor
positive/human epidermal growth factor receptor 2 negative (HR+/HER2-)
advanced breast cancer (ABC) treated with endocrine therapy (ET) +/-
ribociclib. Proffered paper presented at the European Society of Medical
Oncology Congress; September 16-21, 2021; Lugano, Switzerland.
14. Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus
endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307-316.
doi:10.1056/nejmoa1903765
15. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus
Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382(6):514-524.
doi:10.1056/NEJMoa1911149
16. Slamon DJ, Neven P, Chia S, et al. Overall survival (OS) results of the
Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone
receptor--positive (HR+), human epidermal growth factor 2--negative
(HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) +/-
ribociclib (RIB). Presented at the European Society of Medical Oncology
Congress; September 29, 2019; Barcelona, Spain.
17. Slamon DJ, Neven P, Chia S, et al. Updated overall survival (OS) results
from the Phase III MONALEESA-3 trial of postmenopausal patients (pts)
with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant
(FUL) +/- ribociclib (RIB. Presented at the American Society of Clinical
Oncology Annual Meeting; June 5, 2021; Chicago, USA.
18. Tripathy D, Im S-A, Colleoni M, et al. Updated overall survival (OS)
results from the phase III MONALEESA-7 trial of pre- or perimenopausal
patients with HR+/HER2- advanced breast cancer (ABC) treated with
endocrine therapy (ET) +/- ribociclib. Presented at the San Antonio
Breast Cancer Symposium; December 9, 2020; San Antonio, USA.
19. Yardley D, Nusch A, Yap YS, et al. Overall survival (OS) in patients
(pts) with advanced breast cancer (ABC) with visceral metastases (mets),
including those with liver mets, treated with ribociclib (RIB) plus
endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials. Presented
at the American Society of Clinical Oncology (ASCO) Annual Meeting; June
2020; Chicago, USA.
20. O'Shaughnessy J, Stemmer SM, Burris HA, et al. Overall survival subgroup
analysis by metastatic site from the Phase III MONALEESA-2 study of
first-line ribociclib + letroz21ole in postmenopausal patients with
HR+/HER2- advanced breast cancer. Presented at the San Antonio Breast
Cancer Symposium; December 7-10, 2021; San Antonio, USA.
21. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast
cancer stage at diagnosis and cancer-specific survival by race and
ethnicity in the United States [published correction appears in JAMA.
2015 Jun 9;313(22):2287]. JAMA. 2015;313(2):165-173.
doi:10.1001/jama.2014.17322
(MORE TO FOLLOW) Dow Jones Newswires
September 17, 2024 12:55 ET (16:55 GMT)
Ausgewählte Hebelprodukte auf Novartis
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Novartis
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Novartis AG
Analysen zu Novartis AG
Datum | Rating | Analyst | |
---|---|---|---|
02.10.2024 | Novartis Neutral | Goldman Sachs Group Inc. | |
18.09.2024 | Novartis Neutral | Goldman Sachs Group Inc. | |
11.09.2024 | Novartis Buy | UBS AG | |
05.09.2024 | Novartis Neutral | Goldman Sachs Group Inc. | |
03.09.2024 | Novartis Hold | Jefferies & Company Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
11.09.2024 | Novartis Buy | UBS AG | |
19.07.2024 | Novartis Kaufen | DZ BANK | |
19.07.2024 | Novartis Buy | Goldman Sachs Group Inc. | |
19.07.2024 | Novartis Buy | UBS AG | |
18.07.2024 | Novartis Outperform | Bernstein Research |
Datum | Rating | Analyst | |
---|---|---|---|
02.10.2024 | Novartis Neutral | Goldman Sachs Group Inc. | |
18.09.2024 | Novartis Neutral | Goldman Sachs Group Inc. | |
05.09.2024 | Novartis Neutral | Goldman Sachs Group Inc. | |
03.09.2024 | Novartis Hold | Jefferies & Company Inc. | |
23.07.2024 | Novartis Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) |
Datum | Rating | Analyst | |
---|---|---|---|
24.06.2024 | Novartis Underweight | Barclays Capital | |
23.04.2024 | Novartis Underweight | Barclays Capital | |
28.03.2024 | Novartis Underweight | Barclays Capital | |
06.02.2024 | Novartis Underweight | Barclays Capital | |
21.12.2023 | Novartis Underweight | Barclays Capital |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novartis AG nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen